Abstract
We investigated the effect of an emerging biocompatible ionic liquid, choline dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses unfolding and aggregation of trastuzumab, demonstrating great promise as an additive in the development of stable therapeutic antibody formulations.
Original language | English |
---|---|
Pages (from-to) | 10622-10625 |
Number of pages | 4 |
Journal | Chemical Communications |
Volume | 54 |
Issue number | 75 |
DOIs | |
Publication status | Published - 28 Aug 2018 |